Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Condition(s):Refractory and/or Relapsed Metastatic Solid TumorsLast Updated:March 27, 2024Recruiting
Include Studies Not Open or Pending
Condition(s):Refractory and/or Relapsed Metastatic Solid TumorsLast Updated:March 27, 2024Recruiting
Condition(s):Neuroendocrine Tumors; Adrenal TumorLast Updated:March 8, 2024Not yet recruiting
Condition(s):Diet QualityLast Updated:February 20, 2024Not yet recruiting
Condition(s):Brain TumorLast Updated:July 14, 2023Recruiting
Condition(s):Polycystic Ovary Syndrome; Obstructive Sleep ApneaLast Updated:June 27, 2023Recruiting
Condition(s):Kidney Disease, Chronic; End Stage Renal Disease; Kidney ReplacementLast Updated:December 27, 2023Not yet recruiting
Condition(s):Hiv; Vaccine Reaction; Microbial Colonization; Infant DevelopmentLast Updated:January 26, 2024Recruiting
Condition(s):Primary Immune Deficiency Disorder; Immune Deficiency Disease; Bone Marrow FailureLast Updated:November 3, 2023Recruiting
Condition(s):Executive Function; Social Interaction; Disability, DevelopmentalLast Updated:March 29, 2023Recruiting
Condition(s):Moderate Acute MalnutritionLast Updated:September 28, 2023Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.